Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Life Sciences Tools & Services · CIK 0001100682
$344.87
+9.33% · delayed ~15 min
Last price from Oct 21, 2026
$16.97B market value
From CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s FY2025 10-K, filed Feb 18, 2026 · read the filing
CHARLES RIVER LABORATORIES INTERNATIONAL provides engineering, research and consulting services. It took in $4.02B last year, which makes it a mid-sized company. It spends more than it earns — losing about 4 cents on every dollar of sales.
The filing does not provide enough evidence for a clear financial conclusion.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Recent open-market selling by Andrews Nancy C, not under a pre-arranged plan.
$163.4K sold in the last 120 days · Read the filing
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
Significant financial weakness across most measures.
From CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Operating income
$227.3M → $25.2M
Profit
$22.2M → -$144.3M
Earnings per share
$0.43 → -$2.93
Operating margin
5.6% → 0.6%
Measured against FY2024, from the 10-K filed Feb 18, 2026
Deteriorated: -88.9%
$227.3M to $25.2MCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: turned negative
$22.2M to -$144.3MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
How the latest move compares (quote delayed ~15 min), and what was published around it
CRL rose 9.33% on the latest quote. The average Health Care company tracked here moved +1.69%, and the S&P 500 −1.04%. That is 7.6 points above its sector and 10.4 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 14% a year for the next 10 years. Over the last 10 years it grew by about 8% a year.
The essentials
Each answered from the filings, with the numbers behind it.
No. It lost $144.3M last year, losing about 4 cents on every dollar of sales.
No. Sales shrank 0.9% last year.
No. At its current cash flow it could clear its debt in about 2.6 years. For every $1 it owes, it owns $1.82 in assets. Its operating profit does not cover its interest bill — 0.24x against the interest it owes.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it lost $144.3M and generated $737.6M of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 18, 2026Filing for FY2025 | FY202410-K · Feb 19, 2025Filing for FY2024 | FY202310-K · Feb 14, 2024Filing for FY2023 | FY202210-K · Feb 22, 2023Filing for FY2022 | FY202110-K · Feb 16, 2022Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | −0.9% |
| Selling, general and administrative | $743.1M | $751.0M | $747.9M | $665.1M | $619.9M | −1.1% |
| Operating income | $25.2M | $227.3M | $617.3M | $651.0M | $589.9M | −88.9% |
| Operating marginOperating income ÷ revenueWhat is this? | 0.6% | 5.6% | 14.9% | 16.4% | 16.7% | −5.0 pts |
| Interest expense | $107.0M | $126.3M | $136.7M | $59.3M | $73.9M | −15.3% |
| Income before tax | -$99.5M | $93.1M | $581.3M | $623.0M | $480.7M | n/m |
| Net income | -$144.3M | $22.2M | $474.6M | $486.2M | $391.0M | n/m |
| Net marginNet income ÷ revenueWhat is this? | -3.6% | 0.5% | 11.5% | 12.2% | 11.0% | −4.1 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $-2.93 | $0.4342 | $9.25 | $9.54 | $7.75 | n/m |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| CRLCHARLES RIVER LABORATORIES INTERNATIONAL, INC. · this page | 2.0/10 | 4/8 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Exercised stock options — 981 shares at $208.44 ($204.5K)
Holds 5,788 shares after this filing.
Sold on the open market — 981 shares at $308.44 ($302.6K)
Holds 4,807 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Made a Regulation FD disclosure
Read the filingQuarterly report for Q2 FY2026
Operating margin +2.2 pts · Profit turned negative · Earnings per share turned negative — against Q2 FY2025
Read the filingWrite down why you are following CHARLES RIVER LABORATORIES INTERNATIONAL, INC., what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
Coverage from the last 30 days
Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment
Yahoo ·
Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential
Yahoo ·
3 mid-cap stocks walking a fine line
Yahoo ·
Charles River Laboratories International (CRL) Partners With Magellan As Valuation Questions Linger
Yahoo ·
S&P 500 Top Movers: Oct. 21, 2026 US Session
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from CRL's 10-K for fiscal year 2025 (period ending 2025-12-27, filed Feb 18, 2026), reported under the US GAAP taxonomy. View the source filing.
3 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. Accounting had too few reported figures and is left out of the average rather than counted as a weakness, so a company is never marked down for a figure it did not publish. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 8 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 2.0 | 4/8 | 10-K, filed Feb 18, 2026 |
| FY2024 | 4.7 | 6/8 | 10-K, filed Feb 19, 2025 |
| FY2023 | 7.3 | 6/8 | 10-K, filed Feb 14, 2024 |
| FY2022 | 7.3 | 8/8 | 10-K, filed Feb 22, 2023 |
| FY2021 | 8.7 | 5/8 | 10-K, filed Feb 16, 2022 |
| FY2020 | 7.3 | 6/8 | 10-K, filed Feb 17, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
4 of 8 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's. One could not be evaluated and is excluded from the total rather than counted as a failure.
1.81
In the grey zone
For this model, above 2.6 is safe and below 1.1 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — This company has not reported enough of the required figures to calculate this score.
This company has not reported enough of the required figures to calculate this score.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: turned negative
$0.43 to -$2.93Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: −5.0 pts
5.6% to 0.6%Significant
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Deteriorated: −4.1 pts
0.5% to -3.6%Significant
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +9.8%
$194.6M to $213.8MNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: -3.8%
51.1M to 49.2MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Changed: -5.9%
$233.0M to $219.2MNotable
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Aug 5, 2026 — read it.
Deteriorated: turned negative
$52.3M to -$1.5MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: turned negative
$1.06 to -$0.03Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +19.7%
$100.1M to $119.9MSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: −5.2 pts
5.1% to -0.1%Significant
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +2.2 pts
9.7% to 11.9%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Deteriorated: +12.3%
$2.33B to $2.62BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Improved: +5.0%
$182.8M to $192.0MNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: -3.0%
49.2M to 47.7MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Aug 5, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Improved: $13.4M narrower
-$14.8M to -$1.5MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: $0.28 narrower
-$0.31 to -$0.03Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +1.3 pts
-1.5% to -0.1%Notable
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
3 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 11% and 16%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 23 analysts covering this company, as of . Their views, not this site's.
Of 23 analysts publishing on this company, 7 say strong buy, 11 say buy and 5 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 5.8% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 187.7x — a high multiple relative to the current trailing profit.
This company has not reported enough of the required figures to calculate this score.
| -0.9% |
| -3.6% |
| — |
| 1.24x |
| MTDMETTLER TOLEDO INTERNATIONAL INC/ | 8.7/10 | 7/9 | 4.0% | 21.6% | 39.46x | -158.08x |
|---|
| RVTYREVVITY, INC. | 6.0/10 | 6/8 | 3.7% | 8.4% | 73.25x | 0.68x |
|---|
| Median of peers | 7.3/10 | — | 3.8% | 15.0% | 56.36x | -78.70x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Bought on the open market — 10 shares at $297.43 ($3.0K)
Holds 27,762 shares after this filing.
Exercised stock options — 21,132 shares at $194.12 ($4.1M)
Holds 52,728 shares after this filing.
Exercised stock options — 12,429 shares at $208.44 ($2.6M)
Holds 65,157 shares after this filing.
Sold on the open market — 33,561 shares at $300.00 ($10.1M)
Holds 31,596 shares after this filing.
Exercised stock options — 573 shares at $164.30 ($94.1K)
Holds 2,011 shares after this filing.
Sold on the open market — 573 shares at $285.24 ($163.4K)
Holds 1,438 shares after this filing.
Exercised stock options — 2,039 shares at $194.12 ($395.8K)
Holds 6,846 shares after this filing.
Sold on the open market — 2,039 shares at $294.12 ($599.7K)
Holds 4,807 shares after this filing.
Gifted shares — 528 shares
Holds 35,485 shares after this filing.
Exercised stock options — 3,714 shares at $179.66 ($667.3K)
Holds 8,521 shares after this filing.
Sold on the open market — 3,714 shares at $279.66 ($1.0M)
Holds 4,807 shares after this filing.
Exercised stock options — 6,500 shares at $179.66 ($1.2M)
Holds 42,513 shares after this filing.
Sold on the open market — 6,500 shares at $279.90 ($1.8M)
Holds 36,013 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 24,042 shares ($8.4M) on or after .
Shares originally obtained via Exercise of stock options.
Filed notice to sell 2,156 shares ($742.5K) on or after .
Shares originally obtained via Exercise of Stock Options.
Filed notice to sell 981 shares ($308.6K) on or after .
Shares originally obtained via Exercise of Stock Options.
Filed notice to sell 33,561 shares ($10.1M) on or after .
Shares originally obtained via Exercise of stock options.
Filed notice to sell 2,039 shares ($599.7K) on or after .
Shares originally obtained via Exercise of Stock Options.
Filed notice to sell 573 shares ($163.3K) on or after .
Shares originally obtained via Stock Option Exercise.
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Published results
Had a director or senior officer leave or join · Held a shareholder vote
Read the filingQuarterly report for Q1 FY2026
Operating margin +4.5 pts · Operating income +60.6% · Profit turned negative — against Q1 FY2025
Read the filingPublished results
Read the filingProxy statement for a shareholder meeting
Read the filingMade a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join
Read the filingAnnual report for FY2025
Operating margin −5.0 pts · Operating income -88.9% · Profit turned negative — against FY2024
Read the filingPublished results
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join
Read the filingMade a Regulation FD disclosure
Read the filingReported another event
Read the filingQuarterly report for Q3 FY2025
Operating margin +1.7 pts · Profit -21.9% · Earnings per share -18.8% — against Q3 FY2024
Read the filingPublished results
Read the filingHad a director or senior officer leave or join
Read the filingHad a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingQuarterly report for Q2 FY2025
Operating margin −5.1 pts · Profit -44.4% · Earnings per share -41.7% — against Q2 FY2024
Read the filingChartMill ·
Primary sources and further research